Frankenfield Christopher James

Frankenfield Christopher James is listed in filings as Chief Financial Officer at Xilio Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jan 5, 2026, including sale activity. Recent filings connect the profile to Xilio Therapeutics, Inc. (XLO). The current snapshot covers public activity from Aug 6, 2024 to Jan 5, 2026. Reported amounts are shown as $4.5K to $835.5K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.